

**Composition :** Trimetazidine

Dihydrochloride 20mg & Modified release 35mg Tablet.

**Indications :** This tablet is indicated for the treatment of Ischaemic heart disease (angina pectoris, sequelae of infarction), adjuvant symptomatic treatment of vertigo and tinnitus, adjuvant treatment of the decline visual acuity and visual field disturbances, presumably of vascular origin.

**Dosage and administration :** Trimet One tablet (20mg) thrice daily after meals. Trimet-MR one tablet twice daily at mealtimes in the morning and evening. Or as directed by the registered physician.

**Contraindication :** Hypersensitivity to Trimetazidine Dihydrochloride.

**Side effects :** Trimetazidine is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.

**Pregnancy and lactation :** Trimetazidine is not generally recommended during pregnancy. There is no information on the secretion of Trimetazidine into breast milk. However, breast-feeding should be discontinued if the use of Trimetazidine is considered essential. Pregnancy Category **C** by FDA.

**Pediatric use :** Safety and efficacy in children have not been established with

## Trimet

Film Coated Tablet

Trimetazidine.

**Drug interactions :** No drug interactions have so far been reported. In particular, no interactions of Trimetazidine with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.

**Packing : Trimet :** 5x10's tablets in blister pack.

**Trimet-MR :** 2x14's tablets in blister pack.